Biogen's $1.8 Billion Acquisition Bolsters Immunology Portfolio

2024-05-24

交易

孤儿药免疫疗法临床1期并购引进/卖出

On May 22nd, 2024, the biopharmaceutical company Biogen announced its acquisition of HumanImmunology Biosciences (HI-Bio) for a staggering $1.8 billion. This strategic move aims to expand Biogen's foothold in the burgeoning field of immunology.

The core of this acquisition is HI-Bio's lead candidate drug, felzartamab, a CD38 antibody that has received Breakthrough Therapy Designation (BTD) and Orphan Drug Designation (ODD) from the FDA for the treatment of primary membranous nephropathy (PMN) and antibody-mediated rejection (AMR) in kidney transplant recipients. Felzartamab is currently in phase I/II clinical trials.

Felzartamab was initially developed by MorphoSys for the treatment of multiple myeloma, as it selectively targets and eliminates CD38-positive cells, which play a crucial role in antibody-driven diseases. In November 2022, Teneobio secured the exclusive rights to develop and commercialize felzartamab outside of Greater China.

In addition to felzartamab, Biogen will also gain access to HI-Bio's early-stage pipeline, including the anti-C5aR1 antibody izastobart, which is in phase I trials, and a mast cell program currently in the exploratory stage.

Interestingly, just days before announcing the HI-Bio acquisition, Biogen had terminated the development of two neurological pipeline candidates. The company halted the further development of the antisense oligonucleotide (ASO) drug BIIB105 (ION541) for amyotrophic lateral sclerosis (ALS), as well as the decision not to exercise its option to develop BIIB121, an ASO drug intended to restore ubiquitin protein expression in Angelman syndrome patients.

This juxtaposition of acquisitions and pipeline pruning underscores Biogen's strategic focus on bolstering its immunology portfolio, particularly in the areas of kidney diseases, where there is a significant unmet medical need. The addition of felzartamab and other early-stage assets aims to complement Biogen's existing product offerings and solidify its expertise in immunology.

As the biopharmaceutical landscape continues to evolve, Biogen's $1.8 billion investment in HI-Bio reflects the company's commitment to diversifying its pipeline and positioning itself at the forefront of innovative immunotherapies.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构